Fevzi Yalniz, MD
Hematology · Lexington, KYNPI 1114452679
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $280 of the $405 with a category attached, or 69.1%. 6 manufacturers reported payments, led by Acrotech Biopharma Inc. at 30.9% of the total. 2025 is the largest year on record at $180, 2.2 times the $82 reported in 2022.
Across 6 payments — averaging $67.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$125
- Medexus Pharma, Inc.$84
- Bristol Myers Squibb$82
- Sanofi$73
- Stemline Therapeutics Inc.$24
- Gilead$17
Across 13 payments — averaging $6176.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$29K
- Deciphera Pharmaceuticals Inc.$27K
- Bristol Myers Squibb$25K
What the payments were for
- Speaking & faculty fees$12531%
- Food & beverage$28069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 1 | $125 |
| Medexus Pharma, Inc. | 1 | $84 |
| Bristol Myers Squibb | 1 | $82 |
| Sanofi | 1 | $73 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Gilead | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Beleodaq$125
How this compares
Too few hematology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BosulifBosutinib | 33 | $630,005 |
| BrukinsaZanubrutinib | 32 | $447,060 |
| JakafiRuxolitinib Phosphate | 20 | $302,111 |
| ScemblixAsciminib Hydrochloride | 12 | $253,325 |
| TasignaNilotinib Hcl | 19 | $245,631 |
| IclusigPonatinib Hcl | 12 | $232,111 |
| VenclextaVenetoclax | 58 | $190,028 |
| Lenalidomide | 11 | $150,318 |
| CresembaIsavuconazonium Sulfate | 20 | $110,571 |
| Posaconazole | 18 | $33,901 |
| Imatinib Mesylate | 22 | $25,785 |
| Fondaparinux Sodium | 11 | $18,250 |
| Acyclovir | 167 | $2,748 |
| Fluconazole | 29 | $1,844 |
| Ondansetron OdtOndansetron | 15 | $1,027 |
Paid to pharmacies, not to this prescriber.
Other hematology in Lexington
- Reinhold MunkerLexington$8K
- Shams ShakilLexington$1K
- Rachel HarperLexington$473
- Gregory MonohanLexington$133
- Judith LinLexington$61
- Roger HerzigLexington$53
- Rupinder BrarLexington$51
- Zena ChahineLexington$13
- Robert EmmonsLouisville$8K
- Hassaan YasinLouisville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.